Living with DMD: Inspiring each other’s futures
Santhera is putting patient needs at the heart of its rare disease speciality business. Chief Executive Officer Thomas Meier, PhD, talks about the company’s mission – and how rationalising Europe’s drug review systems could help patients.
Progress in health and social care in European countries is helping many boys with Duchenne muscular dystrophy (DMD) to extend their lives beyond what was once dreamed possible, and to take control of their lives as they grow up and become men.
Shares in Solid Biosciences plunged yesterday after the FDA placed a clinical hold on the trial of its gene therapy for Duchenne muscular dystrophy (DMD) following a serious adverse reactions in one patient.
Project will initially focus on DMD but could benefit other rare diseases
Swiss company to appeal regulators’ decision.